Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to Carboplatine Based Chemotherapy in Early "Triple Negative" Breast Cancer

NCT04335669 is registered in ClinicalTrials.gov with Lund University Hospital as lead sponsor.

NCT NCT04335669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04335669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to Carboplatine Based Chemotherapy in Early "Triple Negative" Breast Cancer
Lead sponsor
Lund University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 20, 2019
Completion date
September 30, 2035
Enrollment
325 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast neoplasms